Lupin Ltd. Stock Sees Decline in Performance, Underperforms Sector

Lupin Ltd., a leading pharmaceutical company in the largecap industry, has recently seen a decline in its stock performance. On November 5th, 2024, the company's stock lost -3.56%, underperforming the sector by -2.52%. This marks the second consecutive day of losses for Lupin, with a total decline of -3.63% in this period.

The stock's intraday low was recorded at Rs 2118.95, a decrease of -3.08% from the previous day. While Lupin's moving averages are higher than the 100-day and 200-day averages, they are currently lower than the 5-day, 20-day, and 50-day averages.

In comparison to the overall market performance, Lupin's stock has underperformed. On the same day, the Sensex only saw a decline of -0.11%, while Lupin's performance was -3.57%. Over the past month, Lupin's stock has also seen a decline of -4.06%, while the Sensex's performance was -3.66%.

Despite these recent declines, MarketsMOJO has given a 'Hold' rating for Lupin's stock. As a leading player in the pharmaceutical industry, Lupin continues to be a strong and stable company in the largecap market. Investors should keep an eye on the company's performance in the coming days.